Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 4/20 | 0.58 |
| ▸ | BCHE | P06276 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540981 | 0.89 | HRH3 (0.71) | LMNAHRH3ACHEBCHEL3MBTL1 | |
| SCHEMBL16706846 | 0.86 | LMNA (0.62) | LMNAHRH3MAOBALDH1A1KMT2A | |
| SCHEMBL14538249 | 0.85 | PLA2G10 (0.61) | LMNAACHEBCHEL3MBTL1HDAC8 | |
| SCHEMBL12763727 | 0.83 | CNR2 (0.67) | HRH3ACHEBCHEL3MBTL1MAOB | |
| SCHEMBL375111 | 0.81 | KDM4E (0.68) | LMNAHRH3BCHEL3MBTL1MAOB | |
| SCHEMBL16187980 | 0.81 | ACHE (0.63) | HRH3ACHEBCHEL3MBTL1HDAC8 | |
| SCHEMBL4885900 | 0.81 | HDAC8 (0.50) | ACHEBCHEL3MBTL1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL11608574 | 0.79 | KDM4E (0.66) | HRH3BCHEL3MBTL1MAOBCNR2 | |
| Benzoic Acid SCHEMBL4162737 | 0.79 | MEP1B (0.55) | LMNAACHEBCHEL3MBTL1HDAC8 | |
| SCHEMBL4289838 | 0.78 | HDAC8 (0.66) | HRH3ACHEBCHEHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1819669-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | HDAC1, HDAC10, HDAC6 | LMNA 1567/4885HRH3 33/4885ACHE 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.